CellaVision AB (CEVI) AI Stock Analysis

• Market Cap: $4.32B
• Dividend Yield: 1.36%
• Average Volume (3M): 14.16K
• Price to Earnings (P/E): 28.4
• Beta (1Y): 0.89
• Revenue Growth: 5.60%
• EPS Growth: 7.72%
• Country: SE
• Employees: 228
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): 1.70
• Shares Outstanding: 23,851,547
• 10 Day Avg. Volume: 13,109
• 30 Day Avg. Volume: 14,162
• PEG Ratio: 3.75
• Price to Book (P/B): 5.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 70.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 72 Outperform
• Price Target: kr207.00 ▲(14.36%Upside)

CellaVision AB's strong financial performance and stable balance sheet are the primary drivers of its stock score. While technical indicators show some short-term weakness, longer-term trends remain supportive. The valuation is reasonable but not overly compelling, with a moderate P/E ratio and a modest dividend yield.

CellaVision AB Business Overview & Revenue Model

Company Description

CellaVision AB (publ) develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company provides CellaVision DM1200 and CellaVision DM9600, which automatically capture digital images of cells from blood smears and body fluid preparations; and CellaVision DC-1, an analyzer. It also offers CellaVision Peripheral Blood Application that enables laboratories to automate, standardize, and simplify morphological examination of peripheral blood smears; CellaVision Advanced RBC Application, which enables to perform comprehensive examination of red blood cell morphology; CellaVision Body Fluid Application that enables laboratories to automate, standardize, and simplify morphological examination of body fluid preparations; and CellaVision Remote Review Software, which removes restrictive geographical constraints from the smear review process. In addition, the company provides CellaVision Server Software that creates a single streamlined workflow within one or multiple testing sites; CellaVision Dashboard, a tool designed to give an at-a-glance view of CellaVision analyzer and reviewer metrics; CellaVision Proficiency Software, a cloud-based software designed to help laboratory managers assess, monitor, and promote staff competency in the area of cell morphology; CellaVision CellAtlas, which combines a series of mini lectures with an extensive cell image library; and CellaVision VET that offers digital solutions for medical microscopy in the field of hematology. It sells its products to hospital and commercial laboratories. CellaVision AB (publ) was incorporated in 1994 and is headquartered in Lund, Sweden.

How the Company Makes Money

CellaVision makes money by selling its proprietary software and hardware solutions to clinical laboratories, hospitals, and other healthcare facilities. The company's revenue model is primarily based on the sale of its digital cell morphology analyzers and the accompanying software licenses. CellaVision also generates income through service agreements and customer support contracts, ensuring continuous operation and maintenance of its systems. Additionally, the company may engage in significant partnerships with distributors and healthcare organizations to expand its market reach and enhance its product offerings, contributing to its earnings.

CellaVision AB Financial Statement Overview

Summary

CellaVision AB exhibits strong financial health with robust revenue growth and profitability. The balance sheet is stable with low leverage, providing resilience against economic fluctuations. Cash flow generation is healthy, although there is potential to enhance free cash flow conversion. Overall, CellaVision is well-positioned in the Medical Devices industry.

Income Statement

CellaVision AB has demonstrated strong growth with a consistent increase in total revenue over the years, achieving a revenue growth rate of 3.41% in the TTM. The gross profit margin is robust at 68.47% for the TTM, indicating effective cost management. The net profit margin of 20.34% reflects solid profitability. Both EBIT and EBITDA margins are strong, at 26.20% and 31.53% respectively, showcasing operational efficiency.

Balance Sheet

The balance sheet of CellaVision is solid with a low debt-to-equity ratio of 0.03, indicating minimal leverage. The equity ratio stands at a healthy 80.31%, showcasing financial stability. Return on equity is impressive at 18.14%, reflecting efficient use of shareholder funds. However, the low liability level might suggest underutilized leverage potential.

Cash Flow

CellaVision's cash flow position is stable with a positive free cash flow growth rate. The operating cash flow to net income ratio is 1.24, indicating good cash generation relative to earnings. However, the free cash flow to net income ratio at 0.44 suggests room for improvement in converting earnings into free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	747.94M	723.22M	677.29M	639.34M	565.55M	471.44M
Gross Profit	512.22M	487.07M	463.04M	438.32M	392.30M	313.04M
EBITDA	236.47M	219.75M	207.25M	190.87M	193.60M	124.60M
Net Income	152.12M	140.72M	130.31M	118.33M	125.34M	89.48M
Balance Sheet
Total Assets	1.04B	1.01B	928.71M	891.75M	825.21M	668.02M
Cash, Cash Equivalents and Short-Term Investments	182.32M	149.43M	121.64M	108.05M	130.29M	102.26M
Total Debt	22.96M	26.85M	64.70M	102.50M	136.65M	132.78M
Total Liabilities	205.34M	196.16M	212.32M	250.12M	281.93M	238.41M
Stockholders Equity	838.53M	815.73M	716.39M	641.63M	543.28M	429.62M
Cash Flow
Free Cash Flow	66.26M	120.69M	109.96M	67.85M	75.41M	37.47M
Operating Cash Flow	188.51M	198.44M	196.44M	137.28M	159.72M	71.12M
Investing Cash Flow	-80.37M	-76.01M	-85.53M	-70.01M	-84.34M	-34.96M
Financing Cash Flow	-88.45M	-95.09M	-97.04M	-90.41M	-48.48M	-35.22M

CellaVision AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 181.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CEVI, the sentiment is Neutral. The current price of 181 is below the 20-day moving average (MA) of 187.33, below the 50-day MA of 187.67, and below the 200-day MA of 207.74, indicating a bearish trend. The MACD of -1.59 indicates Positive momentum. The RSI at 47.11 is Neutral, neither overbought nor oversold. The STOCH value of 37.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CEVI.

CellaVision AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CEVI	72 Outperform	$4.32B	28.38	18.49%	1.36%	5.60%	7.72%
Sector *	46 Neutral	C$194.69M	-3.23	-21.19%	2.62%	21.17%	-0.58%
24C		€106.50M	36.64	10.11%	―	―	―
7XY		€653.06M	76.52	1.21%	5.38%	―	―
6Y4		€160.96M	―	-40.15%	―	―	―
6XP		€159.22M	―	-42.24%	―	―	―
SUS	73 Outperform	kr7.81B	55.33		―	12.41%	-32.19%

CellaVision AB Corporate Events

CellaVision to Release Q2 2025 Financial Report and Host Webcast

CellaVision AB announced it will release its second-quarter 2025 financial report on July 18, 2025, and will host a conference call and webcast for analysts, investors, and media. This event, led by CEO Simon Østergaard, will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders’ perspectives on CellaVision’s market position and growth trajectory.

CellaVision Announces CFO Departure Amidst Continued Growth

CellaVision AB announced the departure of its CFO, Magnus Blixt, who will leave the company on July 18, 2025, after twelve years of service. His contributions have been significant in the company’s growth and success, and the search for his replacement will begin immediately. This change in management comes as CellaVision continues to expand its product portfolio and market presence, maintaining its focus on delivering profitable growth.

CellaVision AB AGM Approves Financials and Strategic Resolutions

At its Annual General Meeting, CellaVision AB resolved to adopt the financial statements for 2024, approve a dividend of SEK 2.50 per share, and re-elect key board members, including Mikael Worning as Chairman. The AGM also authorized the board to repurchase and transfer shares, aiming to optimize capital structure and enhance shareholder value, while facilitating working capital procurement and ownership base expansion.